demonstrated that 2,3,5,4′‐tetrahydroxy‐stilbene‐2‐O‐β‐D‐glucoside (TSG) increased SIRT5 expression to attenuate hepatic steatosis by inhibiting mitochondrial oxidative stress.[25] Consistent with these studies, our results demonstrated that SIRT5 improved mitochondrial dysfunction and thus inhibited mitochondrial oxidative stress and inflammation, thereby protecting hepatocytes against AILI. This evidence concerns the gene SIRT5 and fatty liver disease.